Your selection basket is empty.
Define a selection of ETFs which you would like to compare.
Add an ETF by clicking "Compare" on an ETF profile or by checkmarking an ETF in the ETF search.
Personalis
ISIN US71535D1063
|WKN A2PLTK
Market cap (in EUR)
745 m
Country
United States
Sector
Healthcare
Overview
Description
Personalis, Inc. engages in the provision of advanced genomic tests for cancer. The firm is also involved in providing sequencing and data analysis services to support population sequencing initiatives. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in February 2011 and is headquartered in Fremont, CA.
Healthcare Healthcare Services Miscellaneous Healthcare United States
Financials
Key metrics
| Market capitalisation, EUR | 745 m |
| EPS, EUR | -0.88 |
| P/B ratio | 3.4 |
| P/E ratio | - |
| Dividend yield | - |
Income statement (2025)
| Revenue, EUR | 62 m |
| Net income, EUR | -72 m |
| Profit margin | -116.69% |
What ETF is Personalis in?
There are 11 ETFs which contain Personalis. All of these ETFs are listed in the table below. The ETF with the largest weighting of Personalis is the ARK Genomic Revolution UCITS ETF USD Accumulating.
Latest articles
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.